📊 VYCO Key Takeaways
Is Vycor Medical Inc. (VYCO) a Good Investment?
Despite impressive 17% revenue growth and 84% gross margins indicating sound unit economics, VYCO faces critical financial distress with negative stockholders equity (-4.1M), extreme liquidity crisis (0.12x current ratio), and negative operating cash flow. The company lacks sufficient cash reserves (87K) to service 4.9M in liabilities and sustain ongoing negative burn.
Vycor Medical Inc. Key Strengths (VYCO)
- Revenue growth of 17.2% YoY demonstrates genuine market demand for products
- Exceptional gross margin of 83.8% indicates strong pricing power and operational efficiency in product delivery
- Positive operating income of 33.9K shows business model can approach profitability at operational level
VYCO Stock Risks: Vycor Medical Inc. Investment Risks
- Negative stockholders equity of -4.1M indicates technical insolvency with liabilities exceeding assets
- Critical liquidity crisis with current ratio of 0.12x and only 87K cash against 4.9M total liabilities
- Negative operating cash flow (-13.5K) and free cash flow (-18.7K) indicate company cannot self-fund and is consuming remaining cash reserves
Key Metrics to Watch
- Operating cash flow trend - must turn positive within 1-2 quarters to avoid capital crisis
- Stockholders equity trajectory - must return to positive to eliminate insolvency risk
- Cash burn rate and remaining cash runway - critical given minimal reserves and negative cash generation
Vycor Medical Inc. (VYCO) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
VYCO Profit Margin, ROE & Profitability Analysis
VYCO vs Healthcare Sector: How Vycor Medical Inc. Compares
How Vycor Medical Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Vycor Medical Inc. Stock Overvalued? VYCO Valuation Analysis 2026
Based on fundamental analysis, Vycor Medical Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Vycor Medical Inc. Balance Sheet: VYCO Debt, Cash & Liquidity
VYCO Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Vycor Medical Inc.'s revenue has grown significantly by 34% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.01 indicates the company is currently unprofitable.
VYCO Revenue Growth, EPS Growth & YoY Performance
VYCO Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $436.4K | $20.1K | $0.00 |
| Q3 2025 | $390.9K | $4.9K | $0.00 |
| Q2 2025 | $406.3K | -$10.0K | $0.00 |
| Q1 2025 | $337.0K | -$30.6K | $-0.01 |
| Q3 2024 | $308.6K | $23.4K | $-0.01 |
| Q2 2024 | $406.3K | -$10.0K | $0.00 |
| Q1 2024 | $337.0K | $6.9K | $0.00 |
| Q3 2023 | $308.6K | $23.4K | $-0.01 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Vycor Medical Inc. Dividends, Buybacks & Capital Allocation
VYCO SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Vycor Medical Inc. (CIK: 0001424768)
📋 Recent SEC Filings
❓ Frequently Asked Questions about VYCO
What is the AI rating for VYCO?
Vycor Medical Inc. (VYCO) has an AI grade of D with 85% confidence, based on fundamental analysis of SEC EDGAR filings.
What are VYCO's key strengths?
Claude: Revenue growth of 17.2% YoY demonstrates genuine market demand for products. Exceptional gross margin of 83.8% indicates strong pricing power and operational efficiency in product delivery.
What are the risks of investing in VYCO?
Claude: Negative stockholders equity of -4.1M indicates technical insolvency with liabilities exceeding assets. Critical liquidity crisis with current ratio of 0.12x and only 87K cash against 4.9M total liabilities.
What is VYCO's revenue and growth?
Vycor Medical Inc. reported revenue of $1.9M.
Does VYCO pay dividends?
Vycor Medical Inc. does not currently pay dividends.
Where can I find VYCO SEC filings?
Official SEC filings for Vycor Medical Inc. (CIK: 0001424768) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is VYCO's EPS?
Vycor Medical Inc. has a diluted EPS of $-0.01.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is VYCO's fundamental grade?
Based on our AI fundamental analysis in June 2026, Vycor Medical Inc. has a D grade with 85% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is VYCO stock overvalued or undervalued?
Valuation metrics for VYCO: ROE of N/A (sector avg: 15%), net margin of -3.9% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is VYCO's AI grade for 2026?
Our dual AI analysis gives Vycor Medical Inc. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is VYCO's free cash flow?
Vycor Medical Inc.'s operating cash flow is $-13.5K, with capital expenditures of $5.2K. FCF margin is -1.0%.
How does VYCO compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -3.9% (avg: 12%), ROE N/A (avg: 15%), current ratio 0.12 (avg: 2).